Log in to your Inderes Free account to see all free content on this page.

Vistin Pharma

Less than 1K followers

VISTN

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Vistin Pharma is a Norwegian pharmaceutical company. The company conducts research and development and further production of pharmaceutical substances (API), mainly the substances metformin, codeine phosphate and pholcodine. The substances are mainly used in the treatment of diabetes. The company operates on a global level, with the largest presence in the Nordic market. Vistin Pharma was founded in 2015 and is headquartered in Oslo.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

20.5.

2026

General meeting '26

21.5.

2026

Half year dividend

20.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release4/28/2026, 1:30 PM

Vistin Pharma ASA: Notice of Annual General Meeting 20 May 2026

Regulatory press release4/24/2026, 2:40 PM

2025 Annual Report Vistin Pharma ASA

Regulatory press release4/24/2026, 5:40 AM

Vistin Pharma ASA: First quarter 2026 financial results

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release4/17/2026, 8:30 AM

Vistin Pharma ASA: Invitation to Q1 2026 conference call

Regulatory press release2/20/2026, 6:30 PM

Vistin Pharma ASA: Mandatory notification of trade

Regulatory press release2/12/2026, 10:55 AM

Vistin Pharma ASA (VISTN): Key information relating to the proposed cash dividend

Regulatory press release2/12/2026, 6:50 AM

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results

Regulatory press release12/8/2025, 12:30 PM

VISTN: Financial calendar

Regulatory press release10/31/2025, 6:40 AM

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Regulatory press release10/24/2025, 8:00 AM

Vistin Pharma ASA: Invitation to Q3 2025 conference call

Regulatory press release8/15/2025, 6:00 AM

Vistin Pharma ASA: Second quarter and YTD 2025 financial results

Regulatory press release8/8/2025, 8:00 AM

Vistin Pharma ASA: Invitation to Q2 2025 conference call

Regulatory press release6/4/2025, 6:00 AM

VISTN: Ex dividend NOK 1.25 today

Regulatory press release6/4/2025, 6:00 AM

Ex dividend NOK 1.25 today

Regulatory press release5/23/2025, 9:22 AM

VISTN: Financial calendar

Regulatory press release5/22/2025, 12:59 PM

Vistin Pharma ASA: Minutes from the annual general meeting 2025

Regulatory press release5/22/2025, 9:56 AM

Disclosure of voting rights at AGM in Vistin Pharma ASA

Regulatory press release5/7/2025, 1:30 PM

Vistin Pharma ASA (VISTN): Update from the Election Committee

Regulatory press release5/6/2025, 1:03 PM

Vistin Pharma ASA (VISTN): Mandatory notification of trade and disclosure of large shareholding

Regulatory press release4/29/2025, 9:30 AM

Vistin Pharma ASA: Notice of Annual General Meeting 22 May 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.